Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of XC221 in Healthy Volunteers
NCT03459391Phase 1Completed
- Sponsor
- PHARMENTERPRISES LLC
- Start
- May 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aterixen in influenza and Acute Respiratory Infection (ARI) (3 arms), sponsored by PHARMENTERPRISES LLC. Primary endpoint: Number of Adverse events per treatment arm at Day 28. Started May 2017; status: completed.
02
Drugs
aterixen
03
Conditions
influenzaAcute Respiratory Infection (ARI)
Beyond the preview
Go deeper on NCT03459391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03459391.